Type II alveolar epithelial (AT-II) cells produce pulmonary surfactant proteins that are essential for alveolar function. AT-II is a major target in lung injury, and ineffective repair of damaged alveolar epithelia has been postulated to cause pulmonary fibrosis. Previous studies have shown that tyrosine phosphatase Shp2 is expressed highly in the embryonic lung epithelial buds, and Shp2 activity is required for FGFinduced lung branching morphogenesis. To investigate in vivo function of pulmonary Shp2, we generated alveoli epithelia-specific Shp2-knockout (Shp2 Idiopathic pulmonary fibrosis (IPF) is a commonly lethal respiratory disorder with a largely unknown etiology and limited therapeutic options. The pathological features of IPF include a distorted alveolar architecture and excessive collagen deposition in the pulmonary interstitium with minimal associated inflammation (2-4). Recently, emerging concepts have proposed the importance of the pulmonary epithelium in the initiation of fibrosis. Epithelial growth factors have been shown to protect against fibrotic damage in bleomycin (BLM) animal models, suggesting that IPF is possibly
Type II alveolar epithelial (AT-II) cells are considered defenders of the alveolus, and have been shown to play a key role in the regulation of the alveolar physiology. AT-II cells synthesize and secrete surfactant proteins (SPs), control the volume and composition of the epithelial lining fluid, and replace injured type I alveolar epithelial cells after injury in order to maintain the integrity of the alveolar wall. SPs are a complex mixture of lipid-associated proteins, designated SP-A, SP-B, SP-C, and SP-D, which are critical determinants of alveolar stability and function. The homeostasis of SPs is finely orchestrated throughout life. Until recently, it has been increasingly evident that alterations in the genes affecting surfactant homeostasis underlie the pathogenesis of a number of severe lung diseases that were considered idiopathic (1) .
Idiopathic pulmonary fibrosis (IPF) is a commonly lethal respiratory disorder with a largely unknown etiology and limited therapeutic options. The pathological features of IPF include a distorted alveolar architecture and excessive collagen deposition in the pulmonary interstitium with minimal associated inflammation (2) (3) (4) . Recently, emerging concepts have proposed the importance of the pulmonary epithelium in the initiation of fibrosis. Epithelial growth factors have been shown to protect against fibrotic damage in bleomycin (BLM) animal models, suggesting that IPF is possibly associated with the aberrant activation of the epithelial redevelopment program (5) (6) (7) (8) . Intraperitoneal injection of diphtheria toxin into transgenic mice conditionally expressing the toxin receptor induces direct injury targeting the respiratory epithelia, followed by fibrogenesis (9, 10) . Derangements in the pulmonary surfactants are common clinical findings in patients with IPF, and the genes encoding surfactant proteins are highly variable and predispose individuals to familiar pulmonary fibrosis (11) (12) (13) (14) (15) . Those studies have attempted to correlate the epithelial damage and SP defects with fibrosis, while the underlying molecular mechanism remains elusive.
The protein tyrosine phosphatase Shp2 is a ubiquitously expressed intracellular enzyme that contains two Src homology 2 (SH2) domains and one catalytic protein tyrosine phosphatase (PTP) domain (16 -18) . Shp2 integrates multiple signaling events and mediates a variety of physiological functions (19 -22) . Homozygous mutations in shp2 in mice result in early embryonic lethality during gastrulation due to their inability to properly respond to fibroblast growth factor (FGF) signaling (23) . Heterozygous Shp2-mutant mice with significantly enhanced alterations in a weak mutant allele of EGFR mice (Egfr wa2/wa2 ) exhibit atelectatic lungs with an increased alveolar septal thickness and a remarkable reduction in alveolar space (24) . Previous studies have shown that Shp2 is highly expressed in the embryonic lung and potently induces branching morphogenesis and alveolarization that rely on FGFs (25, 26) . However, little is known about the postnatal function of pulmonary Shp2, and genetic models have not yet been described.
We hypothesize that Shp2 plays an important role in the maintenance of alveolar homeostasis and functional integrity in AT-II cells. This notion was tested by specifically deleting Shp2 in the lung epithelia (Shp2 ⌬/⌬ mice). We report that loss of Shp2 leads to deregulation of the pulmonary surfactants, followed by multiple alveolar defects and spontaneous fibrosis without preceding inflammation. These results provide evidence for a functional requirement of Shp2 in alveolar homeostasis and repair process, against the development of pulmonary fibrosis.
MATERIALS AND METHODS

Generation of transgenic mice
SP-C-rtTA tg/Ϫ and (tetO) 7 CMV-Cre tg/Ϫ transgenic mice (C57BL/6 line; refs. 6, 10, [27] [28] [29] were mated with Shp2 f/f mice (C57BL/6 line; refs. 19 -22) to generate double-transgenic SP-C-rtTA/Shp2 f/f or (tetO) 7 -Cre/Shp2 f/f mice. These mice were mated to generate SP-C-rtTA/(tetO) 7 -Cre/Shp2 f/f triple-transgenic lung alveoli epithelia-specific Shp2-knockout (LASKO) mice. Triple transgenic LASKO and littermate (SP-C-rtTA/Shp2 f/f , (tetO) 7 -Cre/Shp2 f/f and Shp2 f/f ) control mice were used for the experiments. To detect the Shp2-KO allele, a forward primer (5=-CAGTTGCAACTTTCT-TACCTC-3=) in intron 3 and a reverse primer (5=-GCAG-GAGACTGCAGCTCAGTGATG-3=) within intron 4 were used. For the Shp2 f/f and Shp2-WT alleles, a Shp2 f/f primer was used.
Doxycycline (DOX) administration and inducible deletion of Shp2 in AT-II cells
Transgenic mice were maintained in a pathogen-free vivarium according to institutional guidelines. To induce the activation of Cre recombinase in transgenic mice, as described previously (27, 28, 30) , 4-to 6-wk-old mice were fed with DOX (Sigma-Aldrich, St. Louis, MO, USA) in their drinking water (2 mg/ml) for 10 d. After this period of DOX administration, the mice were designated as Shp2 ⌬/⌬ mice.
RT-PCR and real-time PCR
Total RNA from tissues or cells was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The concentration of RNAs was measured using a spectrophotometer (Eppendorf, Hamburg, Germany). Total RNA (5 g) was reverse-transcribed using the PrimeScript II 1st Strand cDNA Synthesis Kit (Takara, Otsu, Japan). Real-time quantitative PCR was performed using the FastStart Universal SYBR Green Master Kit (Roche, Mannheim, Germany). The sequences of the specific primers used were as follows: Shp2, 5=-TCGCG-GAGATGGTTTCAC-3= and 5=-TGGACTTGCCGTCGTTGC-3= (within intron 4); SP-A, 5=-GAGGAGCTTCAGACTGCACTC-3= and 5=-AGACTTTATCCCCCACTGACAG-3=; SP-B, 5=- CTGCT-TCCTACCCTCTGCTG-3= and 5=-CTTGGCACAGGTCATTAG-CTC-3=; SP-C, 5=-ATGGACATGAGTAGCAAAGAGGT-3= and  5=-CACGATGAGAAGGCGTTTGAG-3=; SP-D, 5=-AAGGTCCACG-GGGTGAGAA-3= and 5=-TTTGCCTTGAGGTCCTATGTTC-3=;  thyroid transcription factor 1 (TTF1), 5=-TTGTCCGGGAAAAAC  TCTACAAG-3= and 5=-CCCCTATGGCGCTACAGAGA-3=; Col1␣1,  5=-GCTCCTCTTAGGGGCCACT-3= and 5=-CCACGTCTCACCAT-TGGGG-3=; Col1␣2, 5=-GTAACTTCGTGCCTAGCAACA-3= and  5=-CCTTTGTCAGAATACTGAGCAGC-3=; TGF␤1,5=-CTCCCGTG-GCTTCTAGTGC-3= and 5=-GCCTTAGTTTGGACAGGATCTG-3=; IL-1␤, 5=-GCAACTGTTCCTGAACTCAACT-3= and ATCTTTT-GGGGTCCGTCAACT-3=.
Isolation and purification of AT-II cells
AT-II cells were isolated from control and Shp2 ⌬/⌬ mice using collagenase and differential plating on Matrigel as described previously (30) . Typical yields were ϳ10 6 cells/mouse. Over 95% of cells were AT-IIs, as assessed by cytospin and immunostaining for pro-SPC. Cells were analyzed immediately after isolation.
Transmission electron microscopy
Samples were fixed with 2% glutaraldehyde, 0.8% paraformaldehyde, and 0.1 M cacodylate buffered to pH 7.4. After washing, the cells were stained with osmium and imidazole, dehydrated in graded concentrations of ethanol, and then embedded in Epon epoxy resin. Ultrathin sections were examined using a transmission electron microscope (Tecnai 10; Philips, Amsterdam, The Netherlands).
Immunoblotting analysis
The distal portion of mouse lung tissues or cells were homogenized in RIPA buffer (150 mM NaCl; 50 mM Tris, pH 8.0; 1% Triton X-100; 0.5% sodium deoxycholate; and 0.1% SDS, supplemented with protease and phosphatase inhibitors) before further analysis. Lysates of whole lung tissues or cells (30 g ) were separated by SDS-PAGE and immunoblotted using antibodies against the following proteins: Shp2, SP-A, pro-SP-B, pro-SP-C, SP-D (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); Erk1/2, p-Erk1/2 (Cell Signaling Technology, Danvers, MA, USA); and ␤-actin (Sigma-Aldrich). Scanned immunoblots were representative of Ն3 independent experiments. Densitometry was quantified using NIH ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA).
Bronchoalveolar lavage fluid (BALF) analysis and ELISA assay
The right lung of each mouse was lavaged with 0.4 ml of calcium-and magnesium-free PBS after the trachea was cannulated and the left bronchus was tied. This procedure was repeated 3 times (total volume ϳ1.0 ml, recovery Ͼ80%). BALF from each animal was collected in a plastic tube, cooled on ice, and centrifuged at 930 g at 4°C for 10 min. Cell pellets were resuspended in PBS, and the cell numbers were counted. The BALF supernatants of each experimental mouse were stored at Ϫ70°C before measurement. The amount of cytokine in the BALF supernatant was measured using an ELISA kit (TGF␤1, IL-1␤, TNF-␣; eBioscience Inc., San Diego, CA, USA). Each sample was measured according to the manufacturer's recommendations.
Lung histology and immunohistochemistry
Mice were sacrificed by an injection of pentobarbital. Lungs were equivalently inflation fixed with an intratracheal injection of 4% paraformaldehyde in PBS at 25 cmH 2 O and immersed in the same fixative to preserve pulmonary architecture. The left lung of each mouse was embedded in paraffin using standard procedures. Sections (5 m) were mounted on slides for histological or IHC analysis. IHC analysis was performed using an indirect method with antibody against the ␣-SMA protein (Abcam, Cambridge, MA, USA), and the following stains were applied: hematoxylin and eosin (H&E) for general morphology or Masson's trichrome stain for collagen. Alveolar wall thickness and alveolar space was measured using DP2-BSW software (Olympus, Tokyo, Japan). In brief, slides were screened in a blinded fashion, and 6 images/lung were recorded in fields not containing bronchi or major pulmonary vasculature. A total of 20 random measurements of alveolar wall thickness and alveolar space were recorded in each field. The results are expressed as fold changes compared to the controls.
Measurements of lung collagen and hydroxyproline
Collagen content was determined by quantifying total soluble collagen using the Sircol Collagen Assay kit (Biocolor, Carrickfergus, UK) according to the manufacturer's instructions. The data obtained were expressed as the collagen content of the entire right lung. As a measure of fibrosis, total lung hydroxyproline content was determined by colorimetric assays after acid hydrolysis, as described previously (31) .
Luciferase assay
SP-A, SP-B, SP-C, SP-D promoter (Ϫ500 to ϩ50 bp) activity was measured by using a Dual Luciferase assay (Promega, Madison, WI, USA). MLE-12 cells were cotransfected with PGL3-basic (or SP-A-Luc, SP-B-Luc, SP-C-Luc, SP-D-Luc) and Shp2 siRNA or scramble siRNA (Santa Cruz Biotechnology).
Cells were incubated for 48 h. Dual Luciferase assays were performed, and promoter activity values were expressed as arbitrary units using a Renilla reporter for internal normalization.
Evaluation of lung compliance
Determination of lung compliance was used to evaluate the changes in pulmonary mechanics after intravenous methacholine treatment (Sigma-Aldrich). The lung mechanics of anesthetized and tracheostomized mice were assessed as described previously (32) . Briefly, each anesthetized mouse was placed supine inside a Plexiglas whole-body plethysmograph. The flow rate was monitored with a Fleisch tube connected to the airway in a pressure transducer. Changes in lung volume were measured by detecting pressure changes in the plethysmographic chamber through a port in the connecting tube with a pressure transducer. To measure pleural pressure, a needle (no. 12) with a multiholed tip was directly inserted into the pleural cavity (between fourth and fifth rib at left thorax) through a port in the connecting tube with a differential pressure transducer. Transpulmonary pressure was calculated as the difference between mouth and pleural pressure. The signals of all pressure transducers were continuously computed (MedLab; Nanjing Biotech Instruments, Nanjing, China) by fitting flow, volume, and pressure to an equation of motion. Cumulative dose-effect curves were established, and the provocation dose (PD) of methacholine, which cumulatively produced a 100% increase in lung resistance (PD 100 ) or a 25% decrease in lung dynamic compliance (PD 25 ), was determined for each animal. These values were used as indicates of airway responsiveness. Cumulative doses of 0.0625-0.5 mg/kg methacholine (i.v., via a jugular vein cannula) were administered for a period of 2-5 min/dose, with lung function measurements taken between each dose.
Apoptosis assays
Apoptosis was evaluated by Annexin V staining, TUNEL assay, and immunoblotting detection of activated Caspase 3. In brief, purified AT-II cells were collected and stained with Annexin V-FITC (Roche). Flow cytometry assay was performed using FACSCalibur Flow Cytometer (BD BioSciences, San Jose, CA, USA) according to the manufacturer's recommendations. Paraffin sections of mouse lung tissues were treated according to the protocol of immunofluorescence. The sections were incubated overnight with the antibody against pro-SP-C (Santa Cruz Biotechnology), and then with FITC-conjugated secondary antibody (Invitrogen), followed by analyzing with TUNEL assay (Roche) according to the manufacturer's recommendations. Confocal images of stained lung tissue were examined with an inverted microscope (Carl Zeiss, Göttingen, Germany) using the Zeiss LSM program. Purified AT-II cells were lysed and detected using antibody against the cleaved, active form of caspase 3 (Cell Signaling Technology) according to standard immunoblotting protocols.
Microarray analysis
The whole lungs of Shp2 ⌬/⌬ and control mice (nϭ3/group) were used for microarray analysis. Total RNA was isolated with TRIzol (Invitrogen) according to the manufacturer's recommendations. The purity and yield of RNA were determined by the ratio of OD 260/280 and OD 260 measured using a Nanodrop (Thermo, Waltham, MA, USA). RNA integrity was examined with an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). An aliquot of 2 g of total RNA was used for reverse transcription. After double-stranded cDNA synthesis, a MessageAmpTM II aRNA Amplification Kit (Invitrogen) was used to produce biotin-tagged cRNA. The resulting biotagged cRNAs were fragmented to strands of 35-200 bases in length. The fragmented cRNA was hybridized to an Affymetrix mouse genome 430 2.0 array (Affymetrix, Santa Clara, CA, USA). Hybridization was performed at 45°C with rotation for 16 h. The arrays were washed and stained with streptavidin phycoerythrin on an Affymetrix Fluidics Station 450, followed by scanning on a GeneChip Scanner (Affymetrix). The scanned images were extracted and analyzed to generate raw data files saved as CEL files using GeneChip operating software (GCOS 1.4). R 2.10.0 software and bioconductor packages (http://www.bioconductor.org) were using for array data analysis. GCRMA methods were used to normalize the different arrays. After removing control probes and absent probes, a coefficient of variation (CV) curve was used to find differentially expressed genes. Probesets with CV values greater than the 99% percentile of the distribution corresponding to the CV were identified as significantly differentially expressed genes during infection. To further elucidate the functions of significantly expressed genes during infection, we examined gene ontologies using the Web-based analysis tool GOstat (http://gostat.wehi. edu.au/). The significantly expressed genes were compared to genes that were present on any array as a reference. The GO terms were ranked according to their P value. Differentially expressed probesets were analyzed using the free Webbased Molecular Annotation System (MAS 2.0; http://www. capitalbio.com). After analysis, the pathways were ranked according to their statistical significance by calculating their P value based on a hypergeometric distribution.
Bio-Plex cytokine assay
The Bio-Plex Mouse Cytokine 23-Plex A Panel was used with the Bio-Plex Suspension Array System (Bio-Rad, Carlsbad, CA, USA) to profile the expression of 23 inflammatory mediators. The assays were performed according to the manufacturer's instructions. Briefly, 50 l of the working solution containing multiple microbeads labeled with specific antibodies against each of the aforementioned cytokines was added into each well, washed 3 times with 100 l of Bio-Plex wash buffer, and filtered to dryness. Then, 50 l of BALF or lung tissue lysates diluted 1:1 with the specific Bio-Plex sample diluent was added to each well and incubated for 30 min at room temperature. After a wash step (3 times) with 100 l of Bio-Plex wash buffer, the beads were incubated with 25 l of the detection antibody cocktail for 30 min at room temperature, with each antibody being specific to a single cytokine. After washing 3 additional times with 100 l of Bio-Plex wash buffer, the beads were incubated with 50 l of the streptavidin-phycoerythrin solution for 10 min at room temperature and washed again 3 times. The beads were resuspended in each well with 125 l of the Bio-Plex assay buffer, and the concentrations of each cytokine were determined using the array reader. A parallel standard curve was constructed for each cytokine (nϭ6/group).
BLM administration
Mice (4 to 6 wk old) were treated with DOX in their drinking water (2 mg/ml) for 7 d, followed by intratracheal instillation of BLM (1.5 mg/kg or 3 mg/kg). Mice were sacrificed for fibrotic analyses at 28 d after BLM administration.
Statistical analysis
Data are expressed as means Ϯ se and were assessed for significance by Student's t test or ANOVA, as appropriate. Values of P Ͻ 0.05 were accepted as significant.
RESULTS
Generation of Shp2 conditional knockout in lung epithelia
To investigate in vivo function of pulmonary Shp2, we generated LASKO (SP-C-rtTA/(tetO) 7 -Cre)/Shp2 f/f ) mice by crossing floxed Shp2 (Shp2 f/f ) with mice carrying the human SPC promoter-rtTA and (tetO) 7 -CMV-Cre transgenes (Fig. 1A, B) . DOX was administered to LASKO mice to induce Cre expression and shp2 gene inactivation; these mice are designated as Shp2
mice. An analysis of the genomic DNA from the lungs of Shp2 ⌬/⌬ mice indicated a disruption of the floxed shp2 gene (Fig. 1C) , and the loss of Shp2 in lung epithelia was assessed by assaying mRNA and protein levels comparing to controls ( Fig. 1D and Supplemental  Fig. S1A ). The specificity of Shp2 deletion in the lungs was confirmed by an immunoblotting analysis of various tissues (Supplemental Fig. S1B ). Therefore, we successfully generated an inducible lung-specific Shp2-knockout mouse model.
Shp2
⌬/⌬ mice exhibit impaired alveolar architecture and pulmonary mechanics
The respiratory system of mice arises from the ventral foregut endoderm (embryonic day 9.0), followed by the development of a tree-like system of epithelial tubules and vascular structures, which ultimately gives rise to the mature airways and alveoli (postnatal day 28) (33). Shp2 has been reported to be highly expressed in the embryonic lung and to potently induce growth factordependent branching morphogenesis and alveolarization (26) . In this work, 6-to 8-wk-old mice were used to assess the effect of Shp2 deficiency on adult lung physiological function. We administered DOX daily to adult LASKO mice (4 -6 wk) over the entire experimental period. On d 10 after DOX treatment, the lung tissues were sectioned and their histological alterations were analyzed. As shown in Fig. 2A , B, the loss of Shp2 leads to disrupted alveolar architecture, as evidenced by increased alveolar wall thickness and reduced alveolar space, which agree with previous observations in embryonic Shp2 ϩ/Ϫ lungs in Egfr wa2/wa2 mice (24) . We further performed an electron microscopic examination to observe ultrastructural aberrations in Shp2-deficient AT-II cells (Fig. 2C) . Under normal physiological conditions, lamellar bodies are surrounded by a membrane and contain multilamellar lipid membranes (Fig. 2Ca-c, e-g ) in which pulmonary surfactants are stored, correctly packed, and secreted to reduce alveolar tension and prevent atelectasis. Compared to the controls, lamellar bodies in AT-II cells from Shp2 ⌬/⌬ mice lost their lamellar-like structure and showed massive vacuolization. Some vacuolized lamellar bodies were transformed into large, varying-shaped, multilocular bodies (ref. (1 and Fig. 2Cd, h) . Quantitative analysis shows a significant increase in the number of those aberrant (vacuolized) lamellar-like structure in Shp2 ⌬/⌬ mice compared to controls (Fig. 2Ci) . To further investigate the effect of disorganized lamellar bodies on lung physiology, we used invasive pulmonary function test techniques to determine dynamic lung compliance of the mice in response to increasing doses of methacholine (32) . Shp2 ⌬/⌬ mice exhibit significantly reduced lung compliance at 0.5 mg/kg of methacholine compared to control mice (Fig. 2D) . Reportedly, impaired surfactant production and fibrosis is associated with a decrease in pulmonary compliance (1) . Taken together, these results show that Shp2 deletion leads to impaired alveolar architecture and function.
Shp2 ablation causes reduced surfactant protein production and increased apoptosis with undetectable inflammation
To further examine the effect of Shp2 loss on alveolar epithelial injury, we utilized several approaches. First, total distal lung proteins were extracted, and their levels of SPs were analyzed. Shp2 deficiency significantly reduces the production of SP-A, SP-B, and SP-C but not SP-D (Fig. 3A, B) . In addition, we found that Shp2 regulates the transcription of the ATP-binding cassette subfamily A member 3 (Abca3) gene, which is required for lamellar body formation and transport (Fig. 3C) . These results correlate the specific deletion Shp2 in AT-II cells with alveolar epithelial injury and dysfunctional surfactant products. As reported earlier (34, 35) , we also analyzed the potential effects of SP-C-rtTA, (tetO) 7 -Cre, and DOX administration on SP production and alveolar morphology. As illustrated in Supplemental Fig. S1C -E, the results show that adult lungs from bitransgenic (SP-C-rtTA/(tetO) 7 -Cre) mice appear morphologically normal, with no distinguishable loss of SPs in Shp2 heterozygous transgenic background (Shp2 f/ϩ , C57BL/6 line). Previous studies suggested that defects in SPs and ABCA3 are associated with elevated apoptosis in lung epithelial cells (36 -38) . Next, alveolar epithelial cells were isolated and analyzed using flow cytometry. The results depicted in Fig.  3D indicate a moderate increase in the number of apoptotic cells in Shp2 ⌬/⌬ mice, which was further confirmed with the occurrence of AT-II apoptosis by TUNEL staining and immunoblotting detection of activated caspase-3 in vivo (Fig. 3E, F) . Alveolar damage often induces inflammatory responses, which have been previously proposed as a primary cause of fibrosis (3, 4) . Nevertheless, no apparent leukocyte infiltration was observed using H&E in Shp2 ⌬/⌬ mice ( Fig. 2A) . To determine further whether the alveolar epithelial injury due to Shp2 deficiency is accompanied by inflammation, we compared the number of leukocytes ( Fig. 3G and Supplemental Fig. S1F) ; production of IL-1␤, TNF-␣, and TGF␤ in the BALF (Fig. 3H-J) ; and mRNA levels of IL-1␤, TNF-␣, and TGF␤ in the lung tissues (Supplemental Fig. S1G ) of Shp2 ⌬/⌬ mice and their controls. Our data indicate that the loss of Shp2 in alveoli is independent of inflammatory responses. Collectively, these results demonstrate that Shp2 disruption is essentially coupled to reduced expression of SPs and alveolar epithelial injury with limited inflammation.
Shp2 regulates transcription of SPs though TTF1
Next, we studied the putative mechanism by which Shp2 regulates surfactant proteins. As depicted in Fig. 4A , the lung tissues of Shp2 ⌬/⌬ mice exhibited a markedly reduced level of transcription factor TTF1, which is a well-demonstrated transcription factor that regulates SP expression during lung development and alveolar homeostasis (39 -41) . To further determine the effect of Shp2 on TTF1-regulated surfactant proteins, we performed in vitro biochemical analyses using alveolar epithelial type II MLE-12 cells, which have been suggested to retain the capacity to express surfactant proteins (10) . Figure 4B shows that the siRNA-mediated knockdown of Shp2 suppressed the expression of SP-A, Pro-SP-B, and Pro-SP-C but did not alter the expression of SP-D, which is consistent with in vivo observations (Fig. 3A, B) . MLE-12 cells were further transfected with full-length and truncated variants of Shp2 proteins to analyze the transcription of SPs and TTF1. As described in Fig. 4C , D, the overexpression of Shp2 in MLE-12 cells markedly enhanced the endogenous levels of SPs and TTF1. Consistently, knockdown, truncated and catalytically inactive mutants of Shp2 reduced the expression of SPs and TTF1.
Data show that the N-SH2, C-SH2, and PTP domains of Shp2 are all important for Shp2 to regulate SP transcription. A luciferase assay was performed to confirm the transcriptional regulation of SPs (excluding SP-D) by Shp2 though TTF1 (Fig. 4E) . Therefore, we identified an important role for Shp2 in controlling TTF1-regulated transcription of SPs (excluding SP-D) in the alveolar epithelia.
Shp2
⌬/⌬ mice develop spontaneous interstitial fibrosis with minimal inflammation
Early intra-alveolar fibrotic-like lesions in Shp2
⌬/⌬ mice were observed in histological sections (Fig. 2A) . These findings prompted us to further assess the effect of Shp2 deficiency on lung fibrosis. Masson's trichrome staining of mouse lung sections on d 10 after DOX treatment revealed an increased number of collagen deposition in Shp2 ⌬/⌬ mice (Fig. 5A) . Next, the lungs with the loss of Shp2 were analyzed using collagen and hydroxyproline assays. Shp2 ⌬/⌬ mice exhibit a statistically significant increase in collagen expression (Fig.  5B-D) . In addition, we have evaluated the evolution of fibrotic changes on d 5, 10, 20, and 30 after DOX treatment. At each time point, we performed hydroxyproline and collagen content analysis, as indicated in Supplemental Fig. S2A , B; these finding have clearly revealed that inducible disruption of Shp2 in the AT-II cells sufficiently induced progressive fibrotic alterations, characterized as increased hydroxyproline and collagen contents. To rule out potential effects of the combined toxicity of reverse tetracycline transactivator (rtTA), cre, and DOX in mouse lung fibrosis, we analyzed mRNA levels of collagen I-␣1 and collagen I-␣2 (ColI␣1 and ColI␣2; Supplemental Fig. S2C ) and hydroxyproline content (Supplemental Fig. S2D ) in the lung tissues of Shp2 heterozygous floxed mice. Data show no differences in collagen deposition. Together, our data suggest that alveolar epithelial injury due to Shp2 inactivation leads to spontaneous interstitial fibrosis.
To further access the mechanism of the pathogenesis of fibrosis induced by Shp2 deficiency, mRNA expression profiling was analyzed in lung tissues of Shp2 ⌬/⌬ and control mice (Fig. 5E) . The microarray data show that the expression levels of numerous clinically relevant profibrotic marker genes were markedly elevated in Shp2 ⌬/⌬ mice, and most of the altered expression pertained to genes that are associated with extracellular matrix proteins (Supplemental Fig. S3A and Supplemental Table S1 ). In general, lung tissues become scarred by persistent inflammation, even though the role of inflammation in the progression of pulmonary fibrosis remains controversial. Interestingly, we found that Shp2 ⌬/⌬ mice developed fibrosis without concurrent inflammation, which was characterized further by a panel of multiple global cytokine assays for BALF (Supplemental Fig. S3B ). Overall, these findings indi-D Figure 4 . Loss of Shp2 decreases the expression of TTF1 and SPs. A) TTF1 mRNA levels were decreased in lung tissues of Shp2 ⌬/⌬ mice compared with control mice. TTF1 mRNA levels were quantified by real-time PCR assays. Results were standardized to ␤-actin mRNA (nϭ3/group). B) Reduced expression of SP-A, pro-SP-B, and pro-SP-C in Shp2-knockdown cells. Mouse lung epithelial cell line MLE-12 cells were transfected with Shp2 siRNA or scrambled siRNA (control). At 48 h after transfection, cells were collected and lysed. SP expression levels were detected using immunoblotting analysis. C, D) SP (C) and TTF1 (D) mRNA levels were quantified by real-time PCR assays. MLE-12 cells were transfected with Shp2 siRNA, full-length Shp2, or truncated variants: Shp2⌬N (lacking N-terminal SH2 domain of Shp2), Shp2⌬NC (lacking N-terminal and C-terminal SH2 domains of Shp2), and catalytically inactive Cys-to-Ser mutant Shp2CS. Results were standardized to ␤-actin mRNA (nϭ3/group). E) Activity of SP-A, SP-B, SP-C, and SP-D promoter (Ϫ500 to ϩ50 bp) was measured by using a Dual Luciferase assay. MLE-12 cells were cotransfected with PGL3-basic (or SP-A-Luc, SP-B-Luc, SP-C-Luc, SP-D-Luc) and Shp2 siRNA or scramble siRNA. Dual Luciferase assays were performed using a Renilla reporter for internal normalization. **P Ͻ 0.01, ***P Ͻ 0.001 vs. corresponding control.
cate that the loss of alveolar Shp2 results in endogenous damage to surfactant homeostasis, which is important to trigger the initiation of spontaneous fibrosis with minimal inflammation.
Shp2 plays a central role in FGF-mediated surfactant metabolism and repair programs via GAB/MAPK activation
Pulmonary fibrosis occurs in settings of ineffective epithelial repair. Recent studies have suggested that multiple FGF signals are activated in response to alveolar epithelial injury and function to restore subsequent alveolar integrity against fibrosis (5, 6, 42, 43) . Thus, we asked whether or not Shp2 is involved in the FGF-induced activation in the alveolar epithelia. First, we observed that the total levels of the FGFs (FGF1, FGF2, FGF7, and FGF10) in lungs from Shp2 ⌬/⌬ mice remained unaltered compared to controls (Supplemental Fig. S3C ), suggesting that the conditional inactivation of Shp2 in AT-II cells has no effect on overall FGF levels in alveoli. Whereas, we found that Shp2 is recruited to a FGFR-dependent complex that contains the Gab1 and Gab2 proteins on FGF stimulation (Fig. 6A, B) . This result suggests that the direct interaction between cytoplasmic Shp2 and GAB docking proteins (Gab1 and Gab2) transduces receptor signaling initiated by FGFs, particularly FGF1 and FGF2. Furthermore, knockdown of Shp2 suppresses FGF2-mediated activation of the Erk pathway signal, a common downstream kinase of multiple FGF signals during epithelial homeostasis (Fig. 6C) . We further found that both the Shp2 and FGF signals are positively involved in the regulation of the production of SP-A, Pro-SP-B, and Pro-SP-C but not SP-D, implying a pivotal role for Shp2 in FGF-regulated pulmonary surfactant synthesis (Fig.  6D, E) . In support of this finding, we treated Shp2 ⌬/⌬ mice with Curosurf, a clinical treatment consisting of naturally derived surfactants for immature neonatal lungs (44) . Interestingly, The Curosurf-treated Shp2 ⌬/⌬ mice exhibit attenuated fibrotic lesions, suggesting the importance of SPs in the initiation of fibrosis due to Shp2 deficiency (Fig. 6F) . Collectively, this evidence leads us to propose a model in which endogenous inactivation of Shp2 in AT-II cells leads to alveolar epithelial injury, followed by a repair paradigm that requires the essential involvement of FGF/Shp2/ERK pathway. However, Shp2 deficiency further disrupts FGF-induced SP metabolism, which inevitably contributes to ineffectual epithelial reconstruction. ⌬/⌬ and control mouse lungs (nϭ6/group) were acid hydrolyzed and analyzed for hydroxyproline content as described in Materials and Methods. D) Collagen I-␣1 (ColI␣1) and collagen I-␣2 (ColI␣2) mRNA levels of mouse lungs were quantified by real-time qPCR assays. Results were standardized to ␤-actin mRNA (nϭ6/group). E) mRNA expression levels of the clinical IPF-associated genes were quantified in lung tissues of Shp2 ⌬/⌬ and control mice by quantitative real-time PCR assays. Results were standardized to ␤-actin mRNA (nϭ3/group). **P Ͻ 0.01.
DISCUSSION
Using a genetically modified approach, we show here that ablation of Shp2 specifically in AT-II cells leads to distorted alveolar architecture, decreased pulmonary compliance, excessive extracellular matrix accumulation, and limited inflammation. These features are consistent with the defects observed in the lungs of patients with IPF. Our findings suggest a novel physiological role for tyrosine phosphatase Shp2 in alveolar homeostasis and fibrogenesis, and thus add insight into the pathogenesis of lung fibrosis.
Our results indicated loss of Shp2 in alveoli epithelia is correlated with reduced levels of SPs (SP-A, SP-B, and SP-C) and the lipid transport protein ABCA3. These surfactant-related proteins play critical roles in various aspects of alveolar function (1) . We therefore propose that Shp2 serves as an important regulator of SP (excluding SP-D) synthesis. Numerous studies have demonstrated that TTF1 plays a crucial role in controlling the transcription of SPs (excluding SP-D), whose promoters have TTF1 binding sites (40, 41) . Mechanically, we characterize an important role of Shp2 in regulating TTF1-controlled transcription of SPs (excluding SP-D) and are essential for surfactant homeostasis, though our present evidence cannot the possibility that Shp2 may target other factors to impair the expression of SPs. In addition, decreased expression of ABCA3 was also detected in Shp2 ⌬/⌬ mice. ABCA3 protein is expressed predominantly at the limiting membrane of the lamellar bodies in AT-II cells and plays an important role in the formation of pulmonary surfactants, which consists mainly of phospholipids and specific surfactant proteins (45) . Notably, transgenic mice with heterozygous and/or homozygous SP or ABCA3 deficiencies exhibit to varying extents disorganized lamellar bodies, respiratory defects, and even lethal respiratory distress (1, 14, 46 -48) . We noticed that a recent IPF paradigm is that persistent injurious stimuli in the presence of a genetic or acquired dysfunctional AT-II phenotype results in increased alveolar epithelial injury/apoptosis, eventually leading to fibrosis (3, 4, 10, 49) . Here, our observations in Shp2 ⌬/⌬ mice have correlated Shp2 loss in AT-II cells with alveolar injury, which is characterized by a marked reduction in SPs, disorganized lamellar bodies, and increased apoptosis. We therefore defined a novel role of Shp2 in alveolar homeostasis of its dysfunction inducing alveolar epithelial injury, contributing to inflammation-independent fibrosis.
Shp2 is a ubiquitously expressed phosphatase that has been shown to be either pro-or antiapoptotic in a context-dependent manner (50 -53) . Shp2 demonstrates a proapoptotic effect by positively regulating cell death signaling (50, 51) , yet mediates antiapoptotic effects of growth factors (FGFs) and survival factors (IL-6) (52, 53) . Interestingly, we noticed that genetic inactivation of Shp2 phosphatase in various tissues leads to increased cell apoptosis and reduced cell survival (52, 54 -56) . Transgenic animals containing a catalytically inactive mutant of Shp2 (Shp2-CS) exhibit ischemia-induced damage and neuronal death (56) . Deletion of Shp2 in trophoblast stem cells impairs FGF4 signaling, leading to rapid apoptosis (52) . An inducible abolishment of Shp2 in bone marrow causes increased apoptosis in hematopoietic stem cells and progenitor cell pools (54) . Loss of Shp2 specifically in the retina disrupts the ERK pathway and apoptosis of all retinal cells (55) . Consistent with these findings, loss of Shp2 in the AT-II cells resulted in an increase in the number of apoptotic cells. In addition, ABCA3 and surfactant proteins protect AT-II cells from apoptosis (36 -38) . Together, we therefore proposed those phenotypic observations Shp2 ⌬/⌬ mice, characterized by marked reduction in SPs, disorganized lamellar bodies, and increased levels of apoptosis, which commonly contribute into fibrosis. Further investigation may shed light on the detailed mechanism for causality in SP defects and apoptosis.
Recent studies have indicated that FGF/MAPK/Erk signaling is essentially activated to regulate a finely tuned repair paradigm and prevent fibrosis after diverse injuries (5, 6, 43) . The data in this study further reveal that pulmonary Shp2 plays a central role in the FGF/MAPK/Erk pathway. We found that an interaction between docking proteins (GABs) and cytoplasmic Shp2 rapidly occurs in response to FGF stimulation, and this complex is recruited by the FGF receptor. In this manner, SPs (SP-A, SP-B, and SP-C) are produced for alveolar homeostasis and epithelial repair. Those observations support the importance of Shp2 in both endogenous SP synthesis and the FGF-regulated repair paradigm. It is possible that a variety of endogenous or exogenous alveolar injuries cause reduced production of SPs in AT-II cells, which are necessary, but not sufficient for the initiation of fibrosis. Nevertheless irrespective of whether fibrosis occurs, a default alveolar repair is inevitably activated in terms of SP defects in AT-II cells, posing a potential risk of ineffectual repair and fibrogenesis. We propose when loss of Shp2 results in direct damage to functional alveoli and endogenous SP synthesis, a finely tuned epithelial repair paradigm is required for the prevention of fibrosis. However Shp2 ⌬/⌬ mice in which the regulation of FGF/MAPKdominated signaling is demolished exhibit aberrant fibrotic remodeling. In support of this hypothesis, our ongoing studies further describe the involvement of Shp2 in FGF-repressed TGF␤1/Smad activity during the epithelial-mesenchymal transition. Given that Shp2 is a widespread cytoplasmic regulator in participation of the diverse intracellular signaling events, we reason that Shp2 may play a conserved role in many aspects of alveolar homeostasis and repair in a spatially and temporally regulated manner. Future studies would characterize the roles of Shp2 at the multiple cellular events during fibrosis progression.
The etiology of IPF remains unknown, which, to a large extent, has impeded the development of new therapies for this untreatable disease. Persistent inflammation was originally thought to cause fibrosis. However, the recent competing hypothesis has suggested that a respiratory epithelial injury with an unknown cause may trigger inappropriate fibrosis (1-3) . Here, we demonstrated an essential role of Shp2 in control of surfactant protein synthesis, deregulation of which is sufficient for causing alveolar epithelial injury and contributing to the initiation of fibrotic repair. Those observations provide direct evidence for a causal link between alveolar SP defects and the initiation of pulmonary fibrosis.
In the field of pulmonary fibrosis, the BLM-induced fibrotic model has been widely used to explore fibrotic mechanisms and the development of antifibrotic agents (2, 4) . Mice treated with BLM exhibit transient, inhomogeneous fibrotic responses, usually accompanied by a broader, more complicated inflammatory response and excessive lung tissue injuries, hence the use of this model as an ideal animal model for studying IPF remains largely controversial (2, 3) . To the best of our knowledge, this study is the first to report that targeted disruption of the endogenous Shp2 develops spontaneous fibrosis independent of BLM instillation, even though Shp2 ⌬/⌬ mice are more susceptible and experience sudden death from BLM-induced severe fibrosis, compared to controls (data not shown). H&E staining analysis and collagen content measurements indicated that BLM administration exacerbated the severity of fibrosis in Shp2 ⌬/⌬ mice. In addition, an elevated acute inflammatory response was observed after BLM-induced fibrosis in the Shp2 ⌬/⌬ mice. Those findings suggest that fibrotic lesions produced by the Shp2 
